Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma

奥沙利铂 医学 吉西他滨 养生 肿瘤科 淋巴瘤 药理学 内科学 化疗 癌症 结直肠癌
作者
Jing‐Hua Wang,Hua Wang,Yan-jun Wang,Zhong-Jun Xia,Hui-Qiang Huang,Wen-Qi Jiang,Yue Lu
出处
期刊:Oncotarget [Impact Journals, LLC]
卷期号:7 (23): 35412-35422 被引量:36
标识
DOI:10.18632/oncotarget.8643
摘要

Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive neoplasm with a poor outcome. Novel L-asparaginase-based treatment regimens, such as GELOX (gemcitabine, oxaliplatin, and L-asparaginase) and P-gemox (gemcitabine, oxaliplatin, and pegaspargase), have shown promising results against stage IE/IIE ENKTL. To define the general applicability of P-gemox, in a retrospective analysis we examined the efficacy and safety of P-gemox in a cohort of 117 patients with newly diagnosed or relapsed/refractory ENKTL. Treatment included 2 to 8 cycles of P-gemox: intravenous gemcitabine (1250 mg/m2) and oxaliplatin (85 mg/m2) and intramuscular pegaspargase (2500 IU/ m2) on day 1 and repeated every 2 weeks, or intravenous gemcitabine (1000 mg/m2) on days 1 and 8 and intravenous oxaliplatin (130 mg/m2) and intramuscular pegaspargase (2500 IU/m2) on day 1 and repeated every 3 weeks. Upon completion of treatment, the overall response rate was 88.8%, and responses were similar for newly diagnosed and relapsed/refractory patients. After a median follow-up of 17 months, the 3-year overall and progression-free survival rates were 72.7% and 57.8%, respectively. Multivariate analysis showed that CR after treatment was the most significant factor affecting survival. P-gemox thus appears to be an effective and well-tolerated treatment for patients with ENKTL.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
123~!完成签到,获得积分10
1秒前
ASZXDW完成签到,获得积分10
2秒前
爱笑翠梅发布了新的文献求助10
2秒前
3秒前
喝奶茶睡不着完成签到,获得积分10
8秒前
852应助1huiqina采纳,获得30
9秒前
甜甜圈发布了新的文献求助10
9秒前
欧阳半仙完成签到,获得积分10
10秒前
jessie完成签到,获得积分10
11秒前
cy完成签到,获得积分10
13秒前
潇洒的擎苍完成签到,获得积分10
13秒前
爱笑翠梅完成签到,获得积分20
15秒前
王wangWANG完成签到,获得积分10
15秒前
忐忑的蛋糕完成签到,获得积分10
17秒前
工大机械完成签到,获得积分10
17秒前
科研小辣机完成签到 ,获得积分10
18秒前
高贵的思天完成签到,获得积分10
21秒前
00完成签到,获得积分10
21秒前
25秒前
25秒前
25秒前
朴实草莓完成签到,获得积分20
27秒前
27秒前
hnxxangel完成签到,获得积分10
28秒前
Leone发布了新的文献求助10
30秒前
时尚的雅柏完成签到 ,获得积分10
31秒前
FashionBoy应助火星上盼山采纳,获得10
33秒前
33秒前
Duolalala发布了新的文献求助10
35秒前
35秒前
36秒前
41秒前
43秒前
蓝胖子应助火星上盼山采纳,获得50
45秒前
47秒前
47秒前
yuan发布了新的文献求助10
47秒前
serein应助优秀灵竹采纳,获得10
49秒前
50秒前
MXJ完成签到,获得积分10
51秒前
高分求助中
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Handbook of Qualitative Cross-Cultural Research Methods 600
Very-high-order BVD Schemes Using β-variable THINC Method 568
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3137706
求助须知:如何正确求助?哪些是违规求助? 2788609
关于积分的说明 7787778
捐赠科研通 2444975
什么是DOI,文献DOI怎么找? 1300139
科研通“疑难数据库(出版商)”最低求助积分说明 625814
版权声明 601043